AtriCure, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended September 30, 2026, none of our executive officers or directors adopted, terminated or modified a "Rule 10b5-1(c) trading arrangement" or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K), except as described below.
On August 31, 2026, Karl Dahlquist, our Chief Legal Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Dahlquist's plan provides for the sale of up to an aggregate of 38,513 shares of our common stock between November 30, 2026 and July 1, 2027, or such earlier date on which all transactions under the plan are completed. Transactions under the plan will be based upon pre-established dates and stock price thresholds.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.